1.Difference in lymphocyte heat shock protein 71 (HSP71) expression in soldiers of armed police forces from different climatic zones.
Huasong ZENG ; Chengfeng XIAO ; Xiujing JING ; Miao YANG ; Lei KE ; Qian XU ; Hao TAN ; Fangze LI ; Tangchun WU
Chinese Journal of Industrial Hygiene and Occupational Diseases 2002;20(4):282-284
OBJECTIVETo analyze the difference between basal and heat-inducible levels of lymphocyte heat shock protein 71 (HSP71) expression in soldiers from Beijing, Zhengzhou and Guangzhou.
METHODSFlow cytometry and Comet assay were used to detect the level of HSP71 and DNA damage respectively.
RESULTSComet assay showed that there was no significant DNA damage before and after heat stress at 41 degrees C for 1 h, and also no difference found among the 3 climatic zones(P > 0.05). HSP71 of all soldiers in the 3 zones elevated after stress (P < 0.05). The basal and heat-inducible levels of HSP71 in Beijing soldiers(845.87 +/- 135.60 and 1254. 47 +/- 239.05 mean fluorescence intensity respectively) were higher than those in Guangzhou soldiers(702.73 +/- 184.70 and 861.72 +/- 225.12 mean fluorescence intensity respectively) (P < 0.05).
CONCLUSIONThe differences of lymphocyte HSP71 expression before and after heat stress among the soldiers from Beijing, Zhengzhou and Guangzhou suggest that basal and heat-inducible levels of lymphocyte HSP71 expression may be considered as a valuable index to evaluate heat tolerance of soldiers in different climatic zones.
Climate ; Comet Assay ; DNA Damage ; Flow Cytometry ; Heat Stress Disorders ; metabolism ; Heat-Shock Proteins ; biosynthesis ; Humans ; Lymphocytes ; metabolism ; Military Personnel ; Police
2.Application of nanobody in cancer treatment.
Yue WU ; Xiujing HAO ; Min LI
Chinese Journal of Biotechnology 2017;33(7):1085-1090
Camelidae can produce a unique antibody that lacks light chain called variable heavy chain domain, also known as nanobodies. This antibody contains only one variable region, with high affinity, high stability, strong tissue penetration, efficient expression. Besides, their toxicity and immunogenicity are both low to be used for both therapeutic and diagnostic applications, as well as research tools. In this review, we discuss how nanobody has been explored as therapeutics in oncology, and provide ideas for the further development of nanobody.
3.Dickkopf-1 inhibits the secretion of MUC5AC induced by Mycoplasma pneumoniae P1-C in mouse lung epithelial cells.
Juan SHI ; Chunji MA ; Xiujing HAO ; Haixia LUO ; Min LI
Chinese Journal of Biotechnology 2023;39(1):248-261
Mycoplasma pneumoniae is the most common pathogen of respiratory tract infection in children and adults. Clinical observation shows that M. pneumoniae infection can cause massive mucus secretion in the respiratory tract, which makes the breathing of patients difficult. Studies have shown that M. pneumoniae infection can cause massive secretion of mucin 5AC (MUC5AC). Adhesin P1 plays an important role in the pathogenesis of M. pneumoniae infection by mediating the adhesion of pathogens to host cells, and the C-terminal residues of P1 (P1-C) are immunogenic. This study investigated the molecular mechanism of Wnt/β-catenin signaling pathway inhibitor Dickkopf-1 (DKK1) in the secretion of MUC5AC in mouse airway epithelial cells (MAECs) induced by P1-C. Scanning electron microscope and hematoxylin-eosin staining were used to observe the effect of P1-C on mucus secretion of MAECs. Protein chip was used to detect the secretion of cytokines and analyse the enrichment of related signaling pathways induced by P1-C in MAECs. Periodic acid schiff stain (PAS) staining, Tunel staining and Masson staining were used to detect the damage of the lungs of mouse exposed to P1-C. Immunohistochemistry was used to detect the secretion of MUC5AC expression, and Western blotting was used to reveal the molecular mechanism of DKK1-regulated secretion of MUC5AC induced by P1-C protein in MACES. The results showed that P1-C induced the massive secretion of mucus and inflammatory factors in MAECs. During P1-C infection, DKK1 down-regulated janus kinase 2 (JAK2), phosphorylation signaling and transcription activator 1 (p-STAT1) and phosphorylation signaling and activator of transcription 3 (p-STAT3) expression. Overexpression of DKK1 significantly up-regulated the expression of MUC5AC repressor transcription factor fork-head box protein A2 (FOXA2). At the same time, the expression of MUC5AC induced by P1-C was inhibited significantly. It is speculated that DKK1 can effectively reduce the secretion of MUC5AC in MAECs induced by P1-C by inhibiting the JAK/STAT1-STAT3 signaling pathway and up-regulating the expression of FOXA2.
Animals
;
Mice
;
Epithelial Cells
;
Lung
;
Mucin 5AC/metabolism*
;
Mycoplasma pneumoniae/metabolism*
;
Signal Transduction
4.Recent advances in the application of nanobody technology: a review.
Shan SUN ; Xing TAN ; Xiaoyan PANG ; Min LI ; Xiujing HAO
Chinese Journal of Biotechnology 2022;38(3):855-867
As a malleable and novel tool for antigen recognition and modulation, nanobodies have the advantages of small size, easiness of expression, screening and modification, as well as high affinity and stability. Nanobodies are capable of recognizing more cryptic antigenic epitopes that are difficult to be recognized by traditional antibodies, making them increasingly used in the diagnosis and treatment of various diseases and assays. Nanobodies are also playing an irreplaceable role in the basic research. This review summarized the recent development of nanobodies and their derivatives in the detection of small molecules, pathogenic microorganisms and diagnosis of diseases, as well as in the fields of targeted therapies, cellular and molecular imaging. Broad prospects of nanobodies in the field of protein conformation studies were also reviewed.
Single-Domain Antibodies
5.Efficacy and safety of endoscopic marking with SPOT for gastrointestinal lesions
Jiaxu WANG ; Shanshan WU ; Wenhai WANG ; Rongxue LI ; Yu ZHAO ; Weizhen ZHOU ; Yan WANG ; Xiujing SUN ; Peng LI ; Jianyu HAO ; Shutian ZHANG
Chinese Journal of Digestive Endoscopy 2022;39(9):701-706
Objective:To evaluate the efficacy and safety of SPOT (GI Supply, USA), a new carbon-based permanent marker approved by the Food and Drug Administration (FDA), in the endoscopic marking for gastrointestinal lesions.Methods:A total of 115 patients with gastrointestinal lesions who underwent endoscopic treatment or surgery in Beijing Friendship Hospital or Beijing Chao-Yang Hospital from April 2019 to November 2019 were enrolled in the study. SPOT was used to mark the lesions, and marking points were found during endoscopic treatment or surgery to calculate the effective marking rate by single-group target value method. Adverse events after marking were recorded, and the changes of blood routine test, liver and kidney functions before and after marking were compared.Results:The effective rate of endoscopic marking with SPOT was 99.13% (114/115). The longest marking time was 57 days. There was no puncture of intestinal wall or injection into abdominal cavity during the marking process. One patient developed mild fever after marking. The incidence of adverse events was 23.48% (27/115), which were all unrelated to the test equipment. There was no significant difference in blood routine tests or liver and kidney functions before and after marking ( P>0.05). Conclusion:SPOT produced by GI Supply can effectively mark gastrointestinal lesions without serious adverse events, which meets the requirements of clinical use.